Loading…
Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease
Introduction Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/N...
Saved in:
Published in: | Journal of endocrinological investigation 2021-05, Vol.44 (5), p.979-988 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753 |
---|---|
cites | cdi_FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753 |
container_end_page | 988 |
container_issue | 5 |
container_start_page | 979 |
container_title | Journal of endocrinological investigation |
container_volume | 44 |
creator | Barchetta, Ilaria Ceccarelli, Valentina Cimini, Flavia A. Barone, Eugenio Sentinelli, Federica Coluzzi, Mariagrazia Chiappetta, Caterina Bertoccini, Laura Tramutola, Antonella Labbadia, Giancarlo Di Cristofano, Claudio Silecchia, Gianfranco Leonetti, Frida Cavallo, Maria G. |
description | Introduction
Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease.
Methods
We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting.
Results
NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. Hepatic
DPP4
mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (
n
= 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2–10.21),
p
= 0.022.
Conclusions
This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease’s progression in established NAFLD. |
doi_str_mv | 10.1007/s40618-020-01392-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8049937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2437849956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQtRCIloU_wAFZ4sIl1B9J7FyQVgulSKtyAM6W7Ux2XWXjYDtb7U_iX-KQUgoHLvbY897zPM8g9JKSt5QQcRFLUlNZEEYKQnnDiuoROqciHyWX9eMH8Rl6FuMNIVxwKZ6iM85kxQSpztGPjQt26nVyww63boQxufbU4yXQEYoSu4jd0MIIeRlSf8I6Rm-dTtDiW5f2OO0BjwEiDBawHloc4QjBpRP2Hb5eX27fX1yvv1xllVnIHV076T4u3Bk-B35K2BuIM2u-O0DSxvfO5qoi5EKeoyddZsGLu32Fvl1--Lq5KrafP37arLeFLUWZirKuaVdRrml230lT15oZq5kUxnIjLKWGMGOghbLsqrrtOmFo09XCyq7SouIr9G7RHSdzgNZmy0H3agzuoMNJee3U35nB7dXOH5UkZdPkH16hN3cCwX-fICZ1cNFC3-sB_BQVK7mQGVrVGfr6H-iNn8KQ7SmWPbCGy9y0FWILygYfY4DuvhhK1DwJapkElSdB_ZoENdt49dDGPeV36zOAL4CYU8MOwp-3_yP7E5_8wxo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2513293800</pqid></control><display><type>article</type><title>Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease</title><source>Springer Nature</source><creator>Barchetta, Ilaria ; Ceccarelli, Valentina ; Cimini, Flavia A. ; Barone, Eugenio ; Sentinelli, Federica ; Coluzzi, Mariagrazia ; Chiappetta, Caterina ; Bertoccini, Laura ; Tramutola, Antonella ; Labbadia, Giancarlo ; Di Cristofano, Claudio ; Silecchia, Gianfranco ; Leonetti, Frida ; Cavallo, Maria G.</creator><creatorcontrib>Barchetta, Ilaria ; Ceccarelli, Valentina ; Cimini, Flavia A. ; Barone, Eugenio ; Sentinelli, Federica ; Coluzzi, Mariagrazia ; Chiappetta, Caterina ; Bertoccini, Laura ; Tramutola, Antonella ; Labbadia, Giancarlo ; Di Cristofano, Claudio ; Silecchia, Gianfranco ; Leonetti, Frida ; Cavallo, Maria G.</creatorcontrib><description>Introduction
Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease.
Methods
We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting.
Results
NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. Hepatic
DPP4
mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (
n
= 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2–10.21),
p
= 0.022.
Conclusions
This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease’s progression in established NAFLD.</description><identifier>ISSN: 1720-8386</identifier><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/s40618-020-01392-5</identifier><identifier>PMID: 32852705</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biopsy ; Cardiovascular diseases ; Coexistence ; Dipeptidyl-peptidase IV ; Disease ; Endocrinology ; Gastrointestinal surgery ; Inflammation ; Internal Medicine ; Liver diseases ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolic disorders ; mRNA ; Obesity ; Original ; Original Article ; Peptidase ; Steatosis ; Surgery</subject><ispartof>Journal of endocrinological investigation, 2021-05, Vol.44 (5), p.979-988</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753</citedby><cites>FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753</cites><orcidid>0000-0001-6630-8049</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32852705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barchetta, Ilaria</creatorcontrib><creatorcontrib>Ceccarelli, Valentina</creatorcontrib><creatorcontrib>Cimini, Flavia A.</creatorcontrib><creatorcontrib>Barone, Eugenio</creatorcontrib><creatorcontrib>Sentinelli, Federica</creatorcontrib><creatorcontrib>Coluzzi, Mariagrazia</creatorcontrib><creatorcontrib>Chiappetta, Caterina</creatorcontrib><creatorcontrib>Bertoccini, Laura</creatorcontrib><creatorcontrib>Tramutola, Antonella</creatorcontrib><creatorcontrib>Labbadia, Giancarlo</creatorcontrib><creatorcontrib>Di Cristofano, Claudio</creatorcontrib><creatorcontrib>Silecchia, Gianfranco</creatorcontrib><creatorcontrib>Leonetti, Frida</creatorcontrib><creatorcontrib>Cavallo, Maria G.</creatorcontrib><title>Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Introduction
Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease.
Methods
We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting.
Results
NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. Hepatic
DPP4
mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (
n
= 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2–10.21),
p
= 0.022.
Conclusions
This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease’s progression in established NAFLD.</description><subject>Biopsy</subject><subject>Cardiovascular diseases</subject><subject>Coexistence</subject><subject>Dipeptidyl-peptidase IV</subject><subject>Disease</subject><subject>Endocrinology</subject><subject>Gastrointestinal surgery</subject><subject>Inflammation</subject><subject>Internal Medicine</subject><subject>Liver diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metabolic disorders</subject><subject>mRNA</subject><subject>Obesity</subject><subject>Original</subject><subject>Original Article</subject><subject>Peptidase</subject><subject>Steatosis</subject><subject>Surgery</subject><issn>1720-8386</issn><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9Uk1v1DAQtRCIloU_wAFZ4sIl1B9J7FyQVgulSKtyAM6W7Ux2XWXjYDtb7U_iX-KQUgoHLvbY897zPM8g9JKSt5QQcRFLUlNZEEYKQnnDiuoROqciHyWX9eMH8Rl6FuMNIVxwKZ6iM85kxQSpztGPjQt26nVyww63boQxufbU4yXQEYoSu4jd0MIIeRlSf8I6Rm-dTtDiW5f2OO0BjwEiDBawHloc4QjBpRP2Hb5eX27fX1yvv1xllVnIHV076T4u3Bk-B35K2BuIM2u-O0DSxvfO5qoi5EKeoyddZsGLu32Fvl1--Lq5KrafP37arLeFLUWZirKuaVdRrml230lT15oZq5kUxnIjLKWGMGOghbLsqrrtOmFo09XCyq7SouIr9G7RHSdzgNZmy0H3agzuoMNJee3U35nB7dXOH5UkZdPkH16hN3cCwX-fICZ1cNFC3-sB_BQVK7mQGVrVGfr6H-iNn8KQ7SmWPbCGy9y0FWILygYfY4DuvhhK1DwJapkElSdB_ZoENdt49dDGPeV36zOAL4CYU8MOwp-3_yP7E5_8wxo</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Barchetta, Ilaria</creator><creator>Ceccarelli, Valentina</creator><creator>Cimini, Flavia A.</creator><creator>Barone, Eugenio</creator><creator>Sentinelli, Federica</creator><creator>Coluzzi, Mariagrazia</creator><creator>Chiappetta, Caterina</creator><creator>Bertoccini, Laura</creator><creator>Tramutola, Antonella</creator><creator>Labbadia, Giancarlo</creator><creator>Di Cristofano, Claudio</creator><creator>Silecchia, Gianfranco</creator><creator>Leonetti, Frida</creator><creator>Cavallo, Maria G.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6630-8049</orcidid></search><sort><creationdate>20210501</creationdate><title>Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease</title><author>Barchetta, Ilaria ; Ceccarelli, Valentina ; Cimini, Flavia A. ; Barone, Eugenio ; Sentinelli, Federica ; Coluzzi, Mariagrazia ; Chiappetta, Caterina ; Bertoccini, Laura ; Tramutola, Antonella ; Labbadia, Giancarlo ; Di Cristofano, Claudio ; Silecchia, Gianfranco ; Leonetti, Frida ; Cavallo, Maria G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopsy</topic><topic>Cardiovascular diseases</topic><topic>Coexistence</topic><topic>Dipeptidyl-peptidase IV</topic><topic>Disease</topic><topic>Endocrinology</topic><topic>Gastrointestinal surgery</topic><topic>Inflammation</topic><topic>Internal Medicine</topic><topic>Liver diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metabolic disorders</topic><topic>mRNA</topic><topic>Obesity</topic><topic>Original</topic><topic>Original Article</topic><topic>Peptidase</topic><topic>Steatosis</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barchetta, Ilaria</creatorcontrib><creatorcontrib>Ceccarelli, Valentina</creatorcontrib><creatorcontrib>Cimini, Flavia A.</creatorcontrib><creatorcontrib>Barone, Eugenio</creatorcontrib><creatorcontrib>Sentinelli, Federica</creatorcontrib><creatorcontrib>Coluzzi, Mariagrazia</creatorcontrib><creatorcontrib>Chiappetta, Caterina</creatorcontrib><creatorcontrib>Bertoccini, Laura</creatorcontrib><creatorcontrib>Tramutola, Antonella</creatorcontrib><creatorcontrib>Labbadia, Giancarlo</creatorcontrib><creatorcontrib>Di Cristofano, Claudio</creatorcontrib><creatorcontrib>Silecchia, Gianfranco</creatorcontrib><creatorcontrib>Leonetti, Frida</creatorcontrib><creatorcontrib>Cavallo, Maria G.</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barchetta, Ilaria</au><au>Ceccarelli, Valentina</au><au>Cimini, Flavia A.</au><au>Barone, Eugenio</au><au>Sentinelli, Federica</au><au>Coluzzi, Mariagrazia</au><au>Chiappetta, Caterina</au><au>Bertoccini, Laura</au><au>Tramutola, Antonella</au><au>Labbadia, Giancarlo</au><au>Di Cristofano, Claudio</au><au>Silecchia, Gianfranco</au><au>Leonetti, Frida</au><au>Cavallo, Maria G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J Endocrinol Invest</stitle><addtitle>J Endocrinol Invest</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>44</volume><issue>5</issue><spage>979</spage><epage>988</epage><pages>979-988</pages><issn>1720-8386</issn><issn>0391-4097</issn><eissn>1720-8386</eissn><abstract>Introduction
Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease.
Methods
We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting.
Results
NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. Hepatic
DPP4
mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (
n
= 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2–10.21),
p
= 0.022.
Conclusions
This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease’s progression in established NAFLD.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32852705</pmid><doi>10.1007/s40618-020-01392-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6630-8049</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1720-8386 |
ispartof | Journal of endocrinological investigation, 2021-05, Vol.44 (5), p.979-988 |
issn | 1720-8386 0391-4097 1720-8386 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8049937 |
source | Springer Nature |
subjects | Biopsy Cardiovascular diseases Coexistence Dipeptidyl-peptidase IV Disease Endocrinology Gastrointestinal surgery Inflammation Internal Medicine Liver diseases Medicine Medicine & Public Health Metabolic Diseases Metabolic disorders mRNA Obesity Original Original Article Peptidase Steatosis Surgery |
title | Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A53%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20dipeptidyl%20peptidase-4%20is%20independently%20associated%20with%20the%20presence%20and%20severity%20of%20NAFLD/NASH%20in%20individuals%20with%20and%20without%20obesity%20and%20metabolic%20disease&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=Barchetta,%20Ilaria&rft.date=2021-05-01&rft.volume=44&rft.issue=5&rft.spage=979&rft.epage=988&rft.pages=979-988&rft.issn=1720-8386&rft.eissn=1720-8386&rft_id=info:doi/10.1007/s40618-020-01392-5&rft_dat=%3Cproquest_pubme%3E2437849956%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-4661f513a1172f8b66a2bca287bc3b7c11b02bbede44f56dff7b19f67c8f5a753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2513293800&rft_id=info:pmid/32852705&rfr_iscdi=true |